In life-threatening situations, call 911.

Pap Tests, HPV Tests and Cervical Screening

A test result may mention a virus, changes in cells or a sample the lab could not read. Those findings lead to different kinds of follow-up. The National Cancer Institute’s guide to results explains which words belong to which test and what a clinician may look at before interpreting them.

The cervix and what screening looks for

The cervix is the narrow lower part of the uterus, where it opens into the top of the vagina. The National Cancer Institute describes the small passage through the cervix as the channel between those organs. The cervix is the place from which a sample is collected for cervical screening, as MedlinePlus describes.

UterusCervixVagina

The National Cancer Institute describes screening as looking for disease before symptoms start. Cervical screening looks for cell changes that could become cancer. Some changes are called precancerous because they have the potential to become cancer over time, as MedlinePlus explains. Finding a change through screening can lead to a closer examination of the cells or tissue.

Pap testing and HPV testing

A Pap test looks at the cells themselves. A lab examines a sample from the cervix for cells that look different from normal, including changes associated with HPV. A report may also use the terms Pap smear or cervical cytology. Cytology is the study of cells, and this use of the word refers to cells collected from the cervix.

HPV stands for human papillomavirus, a group of related viruses. The National Cancer Institute explains that the HPV test looks for infection with high-risk types of HPV linked to cervical cancer. MedlinePlus distinguishes long-lasting infections with those types from HPV infections in general when it describes how cervical cancer develops. A positive result shows that high-risk HPV was found in the sample, according to the National Cancer Institute. Sometimes the virus becomes active again after an earlier infection, so a positive result following a negative one need not be a new infection.

When the lab runs both tests on the same sample, the National Cancer Institute calls it a cotest. It can report both whether the sample contained the HPV types the test looks for and whether the cells showed changes. During a clinician-collected sample, an instrument called a speculum holds the walls of the vagina apart so the clinician can see the cervix. A small brush or spatula collects cells. A pelvic exam can include other checks as well, so the names pelvic exam and Pap test refer to different parts of a visit. The page on well-woman visits and routine screening puts cervical screening in the context of preventive care.

What an abnormal or unclear result can mean

The National Cancer Institute describes normal, unsatisfactory and abnormal Pap results. A normal result means the lab did not see abnormal cervical cells. An unsatisfactory result means the sample was difficult to read, for example because there were too few cells or because blood or mucus obscured them. An abnormal result means some of the cells looked different; irritation, infection or hormone changes can explain certain mild findings.

The National Cancer Institute describes low-grade changes as usually associated with HPV. High-grade changes look more abnormal under the microscope and can lead to a closer exam. The word abnormal by itself does not tell which type of change the lab saw. MedlinePlus explains that a screening result can also miss a change or appear abnormal when precancerous or cancerous cells are absent.

How follow-up is chosen

Earlier results, treatments for prior cell changes and the specific finding on the current test can all matter, according to the National Cancer Institute. The same word on a report can therefore lead to different follow-up for different people. The American College of Obstetricians and Gynecologists describes some ways a clinician can gather more information:

  • The lab can sometimes test the original sample again using the other test. This is called reflex testing.
  • The clinician may order another HPV test or cotest later to see if the finding is still present. The professional guidance on repeat testing considers age, the initial result and past results when describing timing.
  • Colposcopy is a closer look at the cervix with a magnifying instrument. If any areas look unusual, the clinician may collect a small piece of tissue, or biopsy, for the lab.

Pap reports describe cells collected in a screening sample. The National Cancer Institute’s discussion of biopsy results explains that a tissue sample can show the kind and extent of a change. See gynecologic procedures for more on how colposcopy and cervical tissue procedures differ.

When the task force recommends screening

The United States Preventive Services Task Force gives routine screening recommendations for people with a cervix who do not have related symptoms, with separate considerations for some medical histories. The task force recommends a Pap test every 3 years from ages 21 to 29. From ages 30 to 65, the task force lists a Pap test every 3 years, a high-risk HPV test every 5 years, or a Pap and HPV cotest every 5 years.

The task force recommends against routine screening before age 21, and after age 65 for those adequately screened in the past who have no other high risk of cervical cancer. Its recommendation after hysterectomy depends on whether the cervix was removed and whether there is a history of serious precancerous changes or cervical cancer. The task force’s clinical considerations also explain why a weakened immune system or a history of serious cell changes can mean following a different plan.

Routine intervals refer to screening before symptoms, whereas follow-up begins with a finding that is already known. The task force discusses these situations separately. Its review explains that testing more often can lead to more examinations and treatment of cell changes that would have gone away on their own. The National Cancer Institute also describes the benefit of finding important changes early, when there is a chance to evaluate them before cancer develops.

Sources